MorphoSys advances pipeline

Thursday 5 May 2022


MorphoSys AG advanced its pipeline of wholly-owned cancer drugs in the first quarter while accelerating sales of Monjuvi, its marketed product for diffuse large B cell lymphoma (DLBCL). Revenue for the quarter was €41.5 million, down by 12% from a year earlier. The 2021 figure benefited from a €16 million milestone payment from development partner GlaxoSmithKline Plc.